LILLY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.
Summary for LILLY
| International Patents: | 30 |
| US Patents: | 1 |
| Tradenames: | 85 |
| Ingredients: | 81 |
| NDAs: | 105 |
Drugs and US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | SECONAL SODIUM | secobarbital sodium | SUPPOSITORY;RECTAL | 086530-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Lilly | ISONIAZID | isoniazid | TABLET;ORAL | 008499-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-001 | Jul 10, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Lilly | ILOSONE | erythromycin estolate | SUSPENSION;ORAL | 061894-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Lilly | ILOSONE | erythromycin estolate | SUSPENSION;ORAL | 061894-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Lilly | FORTEO | teriparatide | SOLUTION;SUBCUTANEOUS | 021318-001 | Nov 26, 2002 | DISCN | No | No | 7,517,334 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lilly | SANDRIL | reserpine | TABLET;ORAL | 009376-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,641,790 | ⤷ Try a Trial |
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | 4,389,393 | ⤷ Try a Trial |
| Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | 5,217,974*PED | ⤷ Try a Trial |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,821,975*PED | ⤷ Try a Trial |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-002 | Nov 21, 2003 | 6,943,166*PED | ⤷ Try a Trial |
| Lilly | PROZAC | fluoxetine hydrochloride | SOLUTION;ORAL | 020101-001 | Apr 24, 1991 | 4,314,081*PED | ⤷ Try a Trial |
| Lilly | SYMBYAX | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 021520-005 | Dec 24, 2003 | 6,960,577 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
| ➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
| ➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
| ➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
| ➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
| ➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
| ➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
| ➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
International Patents for LILLY Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 1732629 | ⤷ Try a Trial |
| Spain | 2728788 | ⤷ Try a Trial |
| China | 1933864 | ⤷ Try a Trial |
| Poland | 1732629 | ⤷ Try a Trial |
| Norway | 20064955 | ⤷ Try a Trial |
| Eurasian Patent Organization | 200601801 | ⤷ Try a Trial |
| Eurasian Patent Organization | 009497 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LILLY Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0273658 | C300171 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811 |
| 0933372 | PA2008006 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| 1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| 0432677 | 7/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
| 2101777 | 2016C/032 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 |
| 1539166 | 92323 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
